Molecular docking studies confirmed direct GPX4 inhibition, and high GPX4 expression in oral cancer biopsies correlated with poor prognosis, highlighting TFP as a promising repositioned drug candidate. This evidence concerns the gene GPX4 and lip and oral cavity carcinoma.